AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00562848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo.
Study NCT04841395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)
Description: Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
Study NCT00698607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month clopidogrel therapy
Description: Use clopidogrel for 12 months
Study NCT03370627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal anti-cd303 antibody
Description: Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
Study NCT01345058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Lacosamide maximum of 200 mg/day, to be titrated as follows:~* Week 1: 50 mg twice a day~* Beginning Week 2: 100 mg twice a day.
Study NCT01345058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: levetiracetam
Description: Low dose ≤1500 mg/day, High dose >1500 mg/day
Study NCT01345058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Low dose ≤1500 mg/day, High dose >1500 mg/day
Study NCT02455908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin®
Study NCT03254537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Organic
Description: Traditional Mediterranean diet comprised of organic ingredients
Study NCT03254537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean conventional
Description: Traditional Mediterranean diet comprised of conventional ingredients
Study NCT03113539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm
Description: On the same day, the subject will do :~1. Modified low-dose, EKG-gated CT without contrast~2. Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols.
Study NCT02838017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesive
Study NCT02838017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile strips
Study NCT04382794 — intervention group
Intervention type: DRUG
Intervention: Retrospective case-control analysis
Description: Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
Study NCT03394924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 1 mg
Description: Two tablets daily for 12 weeks
Study NCT03394924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 2.5 mg
Description: Two tablets daily for 12 weeks
Study NCT03394924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets daily for 12 weeks
Study NCT04136938 — intervention group
Intervention type: OTHER
Intervention: Social marketing campaign
Description: A social marketing campaign of prevention workshop sessions will be performed.
Study NCT01884350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT01702129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR immunoliposomes loaded with doxorubicin
Description: All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
Study NCT04523129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyclASol topical ocular, eye drops
Description: Cyclosporine A solution in vehicle
Study NCT04523129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical ocular, eye drops
Description: Vehicle
Study NCT03626181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation ( Transcranial Magnetic Stimulation)
Description: Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval.
Study NCT01830712 — intervention group
Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
Study NCT02115373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
Study NCT02115373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
Study NCT02907177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
Study NCT02907177 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet of matching placebo administered orally once daily in the morning
Study NCT04578301 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT00396071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: vildagliptin 100 mg
Study NCT00396071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT02566213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02851394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Study NCT02566213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Motor skills measurements
Description: * the kinematics measurements of the right hand with a motion analysis system;~* the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;~* the measurement of position of the moved object with an inductive position encoder.
Study NCT03224728 — intervention group
Intervention type: DEVICE
Intervention: intraocular lens
Study NCT02344667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Study NCT03760432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Custom Corneal Collagen Cross-Linking
Description: Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
Study NCT00688350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral feedback
Description: The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
Study NCT03105180 — intervention group
Intervention type: OTHER
Intervention: A mixture of 2.7% sorbitol-0.54% mannitol solution
Description: Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
Study NCT03353649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Now vs. Later Cue
Description: As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus.
Study NCT03353649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
Study NCT01324011 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adult diabetes family-based weight loss intervention
Description: Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
Study NCT01324011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adult diabetes family-based weight loss intervention
Description: Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
Study NCT00914732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
Study NCT00914732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Vaccinia vaccine liquid formulation delivered at lower dose \[2x10\^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose\] by intradermal (ID) route on Days 0 and 28.
Study NCT00914732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
Study NCT03658395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sacrocolopopexy
Description: The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
Study NCT01381055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
Study NCT01381055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
Study NCT02009553 — intervention group
Intervention type: OTHER
Intervention: Information sheet
Study NCT02009553 — intervention group
Intervention type: OTHER
Intervention: No information sheet
Study NCT03658395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior repair
Description: The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
Study NCT03740919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT03740919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT03740919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT03740919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT01059617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' FluLaval®
Description: Intramuscular injection
Study NCT01059617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Intramuscular injection
Study NCT03213769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical coenzyme Q10 gel
Description: Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
Study NCT02335242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg tablets
Study NCT02335242 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets (resembling Revatio)
Study NCT03063346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate high dose
Study NCT03063346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate low dose
Study NCT03063346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01059617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
Description: Intramuscular injections
Study NCT01059617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
Description: Intramuscular injections
Study NCT01307501 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cryoablation
Description: Application of extremely cold temperatures to the identified tumor(s).
Study NCT01475526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: El Valor de Nuestra Salud Store Intervention
Description: Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
Study NCT04679129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42
Description: Oral tablets
Study NCT03213769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carpabol gel
Description: placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
Study NCT04679129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT04431102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PILATES METHOD
Description: It is intended that the Pilates program have a duration of four weeks and its realization does not suppose an excessive consumption of resources. Therefore, it must have a series of characteristics: low supervision and easily realizable by all patients, which implies flexibility in the schedule. In this sense the sessions of Pilates is adjusted to these assumptions and the Pilates monitor offers several schedules on diferent days of week.~The pregnant women assigned to the intervention group will be supervised by the midwifery of reference and trained by a Pilates monitor who will explain the training program and resolve the doubts raised by the women.~The therapeutic control will be carried out by telephone call and clinical history review between the eighth and tenth day.
Study NCT01164059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 10, 15, or 20 mg / day
Study NCT01164059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol
Description: Flupentixol 6, 9, or 12 mg / day
Study NCT01164059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine 400, 600, or 800 mg / day
Study NCT01164059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole 10, 15, or 20 mg / day
Study NCT01164059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol 3, 4.5, or 6 mg / day
Study NCT04824560 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blood pressure education
Description: One page teaching protocol performed by pharmacy students; phone follow-up
Study NCT04024852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group
Description: When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
Study NCT04511923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulised heparin
Description: Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days
Study NCT05063318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin alone
Description: The dose of lurbinectedin during Parts A and B will be 3.2 mg/m² for all patients when administered without itraconazole.
Study NCT05063318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin+Itraconazole co-administration
Description: The dose of lurbinectedin when given in combination with itraconazole for the initial three patients in Part A will be 0.8 mg/m², and in Part B is susceptible to be adjusted properly if deemed necessary based on exposure and safety experience in Part A.
Study NCT03203746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene + SRP
Study NCT03203746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP only
Study NCT03542253 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: After surgical treatment, pathological specimens were extracted to obtain pathological results
Study NCT01987843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Low
Study NCT01987843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-Middle
Study NCT01987843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303-High
Study NCT03120624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo image-guided biopsy
Study NCT03120624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03120624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Tetrafluoroborate
Description: Given IV
Study NCT03120624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03120624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo TFB-PET